Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lothar Hertle

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Journal of Andrology|June 30, 2004
Cryopreservation of sperm from adolescents and adults with malignanciesAxel Kamischke, Herbert Jürgens, Lothar Hertle, et al.
Oncology|August 21, 2008
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patientsEdwin Herrmann, Stefan Bierer, Joachim Gerss, et al.
Expert Review of Anticancer Therapy|June 6, 2009
Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agentsThomas Köpke, Stefan Bierer, Christian Wülfing, et al.
European Urology|January 24, 2007
Multiorgan failure 17 years after initial stone therapy: forgotten ureteral stent in a horseshoe kidneyGerald Pühse, Hansjürgen Piechota, Christian Scheffold, et al.
Expert Review of Anticancer Therapy|December 27, 2005
The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implicationsEdwin Herrmann, Martin Bögemann, Stefan Bierer, et al.
International Journal of Oncology|May 5, 2005
Cox-2 and Her2/neu co-expression in invasive bladder cancerElke Eltze, Christian Wülfing, Dagmar Von Struensee, et al.
European Urology|December 12, 2003
Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapyChristian Wülfing, Elke Eltze, Dagmar von Struensee, et al.
Urologic Oncology|December 17, 2013
Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patientsReemt Hinkelammert, Okyaz Eminaga, Olaf Bettendorf, et al.
Journal of Cancer Research and Clinical Oncology|July 2, 2008
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinibEdwin Herrmann, Joachim Gerss, Stefan Bierer, et al.
World Journal of Urology|January 27, 2007
Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapyChristian Wülfing, Hermann van Ahlen, Elke Eltze, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Journal of Andrology|June 30, 2004
Cryopreservation of sperm from adolescents and adults with malignanciesAxel Kamischke, Herbert Jürgens, Lothar Hertle, et al.
Oncology|August 21, 2008
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patientsEdwin Herrmann, Stefan Bierer, Joachim Gerss, et al.
Expert Review of Anticancer Therapy|June 6, 2009
Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agentsThomas Köpke, Stefan Bierer, Christian Wülfing, et al.
European Urology|January 24, 2007
Multiorgan failure 17 years after initial stone therapy: forgotten ureteral stent in a horseshoe kidneyGerald Pühse, Hansjürgen Piechota, Christian Scheffold, et al.
Expert Review of Anticancer Therapy|December 27, 2005
The endothelin axis in urologic tumors: mechanisms of tumor biology and therapeutic implicationsEdwin Herrmann, Martin Bögemann, Stefan Bierer, et al.
International Journal of Oncology|May 5, 2005
Cox-2 and Her2/neu co-expression in invasive bladder cancerElke Eltze, Christian Wülfing, Dagmar Von Struensee, et al.
European Urology|December 12, 2003
Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapyChristian Wülfing, Elke Eltze, Dagmar von Struensee, et al.
Urologic Oncology|December 17, 2013
Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patientsReemt Hinkelammert, Okyaz Eminaga, Olaf Bettendorf, et al.
Journal of Cancer Research and Clinical Oncology|July 2, 2008
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinibEdwin Herrmann, Joachim Gerss, Stefan Bierer, et al.
World Journal of Urology|January 27, 2007
Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapyChristian Wülfing, Hermann van Ahlen, Elke Eltze, et al.
Pageof 4